Pricing
  1. JP-listed companies
  3. Financials
  4. Operating margin (%)

(4586)

Market cap
¥6.6B
P/E ratio
Medrex develops new pharmaceuticals using proprietary skin-patch delivery technology that improves drug effectiveness and reduces side effects.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndOperating margin (%) YoY (%)
Dec 31, 2025-735.5+139.19%
Dec 31, 2024-307.5-90.27%
Dec 31, 2023-3,161+71.11%
Dec 31, 2022-1,847.3-85.46%
Dec 31, 2021-12,709.3+1193.98%
Dec 31, 2020-982.2+2.48%
Dec 31, 2019-958.4-93.68%
Dec 31, 2018-15,164.6+2956.50%
Dec 31, 2017-496.1-91.75%
Dec 31, 2016-6,010.4+126.07%
Dec 31, 2015-2,658.7-30.34%
Dec 31, 2014-3,816.6

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat